

C2 conclude
5. (Twice amended) The composition of claim 4, wherein the concentration of succinate is 10 mM.

C3
12. (Twice amended) The pharmaceutical composition of claim 11, wherein the pH of said composition is about 6.0, the concentration of said succinate is 10 mM, and the composition further comprises about 140 mM sodium chloride.

Please enter the following new claims:

C4
--35. (New) The composition of claim 1, wherein the concentration of succinate is 8 mM to 45 mM.

36. (New) The composition of claim 35, wherein the concentration of succinate is 9 mM to 45 mM.

37. (New) The composition of claim 36, wherein the concentration of succinate is 10 mM to 45 mM.

38. (New) The composition of claim 1, wherein the concentration of succinate is 8 mM to 40 mM.

39. (New) The composition of claim 38, wherein the concentration of succinate is 9 mM to 40 mM.

40. (New) The composition of claim 38, wherein the concentration of succinate is 10 mM to 40 mM.

41. (New) The composition of claim 3, wherein said pharmaceutically active agent is human insulin-like growth factor 1 (IGF-I) or a biologically active variant thereof, wherein said variant is a polypeptide having IGF-I activity and at least 70% sequence identity to human IGF-I.